Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVICTI in Pediatric UCD Subjects Under 2 Years
NCT02246218Phase 4Completed
- Sponsor
- Amgen
- Start
- Dec 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of glycerol phenylbutyrate in urea cycle disorders (UCD), sponsored by Amgen. Primary endpoint: Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia at Day 4. Started Dec 2014; status: completed.
02
Drugs
glycerol phenylbutyrate
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT02246218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246218.